Review Article

Lung cancer is the leading cause of cancer-related death in men and women in the United States.
The chronic lymphocytic leukemia (CLL) development landscape is one of the most dynamic areas in oncology clinical research. During the writing of this manuscript, there were new approvals made, and guidelines were updated.

Non-Hodgkin lymphoma (NHL) represents a heterogeneous group of predominantly mature malignancies originating from B lymphocytes, T lymphocytes, or natural killer cells.

Chronic lymphocytic leukemia (CLL) is a disease that predominantly occurs in older adults; the median age at diagnosis is 71 years. Therefore, the CLL population typically has age-related comorbidities.
Lack of sufficient vitamin B12 intake is often associated with the development of vitamin B12 deficiency anemia, which is a medical condition characterized by a low red blood cell count and vitamin B12.
From 2005 to 2014, the number of ongoing trials of chronic lymphocytic leukemia (CLL) has increased at a compound annual growth rate of 18.4%. This rapid growth in the CLL clinical trial landscape has led to multiple breakthroughs in the management of CLL, which have changed—and will continue to change—the treatment paradigm in the near future.
There have been a multitude of advances in the treatment of metastatic melanoma in the past decade, including approval of newer targeted therapies that often are better tolerated than previously used chemotherapy and immunotherapies.

Results 1 - 7 of 7